Press Release – New York, NY – February 25, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented Aspire Biopharma Holdings Inc. (Nasdaq: ASBP)(Nasdaq: ASBPW), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology, in the closing of a previously announced business combination with PowerUp Acquisition Corp. (Nasdaq:PWUP), a Nasdaq Global Market® listed special purpose acquisition company. On February 20, 2025, Aspire Biopharma shares of common stock and warrants began trading on the Nasdaq Global Market and Nasdaq Capital Market respectively, under the ticker symbols “ASBP” and “ASBPW,” respectively.
On February 19th, 2025 Aspire Biopharma Holdings Inc. entered into a definitive Securities Purchase Agreement, resulting in gross proceeds of $3.0 million. Proceeds from the transaction will support the Company’s general working capital and operating expenses.
The SRFC team was led by partner Arthur Marcus and associate Chance Moore.
